Share this article
Share this article
NEW YORK, Jan. 20, 2021 /PRNewswire/ Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated
Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating
Oxford Immunotec Global PLC ( OXFD or the Company ) (
) relating to its proposed sale to PerkinElmer, Inc. Under the terms of the agreement, OXFD shareholders will receive $22.00 in cash per share they own.
The investigation focuses on whether Oxford Immunotec Global PLC and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether and by how much this proposed transaction undervalues the Company.
Oxford Immunotec Global PLC
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announces the launch of
100 Physicians Find, a monthly survey that takes the pulse of one hundred medical professionals on the front lines of the COVID-19 pandemic about their perspectives, experiences and needs in the face of this global health crisis.
/PRNewswire/ Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Boston Private Financial Holdings,.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of .
Oxford Immunotec Global PLCJanuary 13, 2021 GMT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the start of a collaboration with Valneva. The Company will perform T cell testing on participants receiving Valneva’s inactivated whole-virus COVID-19 vaccine candidate (VLA2001) with the research use only T-SPOT
Discovery SARS-CoV-2 test. The VLA2001-201 study is a randomized Phase I/II clinical study designed to evaluate the safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 virus vaccine candidate in healthy subjects, the first study of its kind performed in Europe.